Ampio Pharmaceuticals, Inc. (AMPE) |
|
0.28 -0.004 (-1.23%)
|
01-27 15:59 |
|
Open: |
0.2835 |
Pre. Close: |
0.2835 |
|
High:
|
0.2899 |
Low:
|
0.28 |
|
Volume:
|
141,467 |
Market Cap:
|
4(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:42:28 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.34 One year: 0.4 |
| Support: |
Support1: 0.2 Support2: 0.17 |
| Resistance: |
Resistance1: 0.29 Resistance2: 0.35 |
| Pivot: |
0.28  |
| Moving Average: |
MA(5): 0.27 MA(20): 0.28
MA(100): 0.52 MA(250): 2.62 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 39.7 %D(3): 38.1 |
| RSI: |
RSI(14): 47.9 |
| 52-week: |
High: 9.75 Low: 0.15 |
| Average Vol(K): |
3-Month: 200 (K) 10-Days: 160 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AMPE ] has closed above bottom band by 36.1%. Bollinger Bands are 83.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 69 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.29 - 0.29 |
0.29 - 0.29 |
|
Low:
|
0.28 - 0.28 |
0.28 - 0.28 |
|
Close:
|
0.28 - 0.28 |
0.28 - 0.28 |
|
Company Description |
|
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado. |
Headline News |
Fri, 27 Jan 2023
6-0 vote acknowledges $88.9m school-budget allocation - YourArlington.com
Fri, 20 Jan 2023
Is Ampio Pharmaceuticals Inc (AMPE) Stock a Smart Investment Friday? - InvestorsObserver
Tue, 17 Jan 2023
AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS - PR Newswire
Sun, 15 Jan 2023
School Committee divided over trip, seeks consensus on financial ... - YourArlington.com
Wed, 04 Jan 2023
AMPE and MCVE updated to reflect further cost inflation - ahdb.org.uk
Tue, 29 Nov 2022
Investors who lost Money with shares of Ampio Pharmaceuticals, Inc ... - BioSpace
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
227 (M) |
| Shares Float |
209 (M) |
|
% Held by Insiders
|
7.5 (%) |
|
% Held by Institutions
|
13.7 (%) |
|
Shares Short
|
12,010 (K) |
|
Shares Short P.Month
|
11,410 (K) |
Stock Financials |
|
EPS
|
-0.1 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.62 |
|
EPS Est Next Year
|
-0.19 |
|
Book Value (p.s.)
|
0.09 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-58.1 |
|
Return on Equity (ttm)
|
-86.9 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.11 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-19 (M) |
|
Levered Free Cash Flow
|
-10 (M) |
Stock Valuations |
|
PE Ratio
|
-3.05 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.11 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-3.44 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
